BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36712921)

  • 41. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
    Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
    Kruger D; Yako YY; Devar J; Lahoud N; Smith M
    PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
    Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
    Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
    Chen J; Chen LJ; Xia YL; Zhou HC; Yang RB; Wu W; Lu Y; Hu LW; Zhao Y
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1117-27. PubMed ID: 23546595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma.
    Jo JH; Kim SA; Lee JH; Park YR; Kim C; Park SB; Jung DE; Lee HS; Chung MJ; Song SY
    BMC Cancer; 2021 Nov; 21(1):1241. PubMed ID: 34794402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
    Parikh DA; Durbin-Johnson B; Urayama S
    J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
    Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
    Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S; Li Y; Liao Z; Wang Z; Wang Z; Li Y; Qian L; Zhao J; Zong H; Kang B; Zou WB; Chen K; He X; Meng Z; Chen Z; Huang S; Wang P
    Gut; 2020 Mar; 69(3):540-550. PubMed ID: 31562239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma.
    Tanase CP; Dima S; Mihai M; Raducan E; Nicolescu MI; Albulescu L; Voiculescu B; Dumitrascu T; Cruceru LM; Leabu M; Popescu I; Hinescu ME
    J Mol Histol; 2009 Feb; 40(1):23-9. PubMed ID: 19160064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma.
    Vychytilova-Faltejskova P; Kiss I; Klusova S; Hlavsa J; Prochazka V; Kala Z; Mazanec J; Hausnerova J; Kren L; Hermanova M; Lenz J; Karasek P; Vyzula R; Slaby O
    Diagn Pathol; 2015 Apr; 10():38. PubMed ID: 25908274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating cancer-associated extracellular vesicles as early detection and recurrence biomarkers for pancreatic cancer.
    Yoshioka Y; Shimomura M; Saito K; Ishii H; Doki Y; Eguchi H; Nakatsura T; Itoi T; Kuroda M; Mori M; Ochiya T
    Cancer Sci; 2022 Oct; 113(10):3498-3509. PubMed ID: 35848896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
    Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
    Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
    van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
    Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
    [No Abstract]   [Full Text] [Related]  

  • 56. Increased serum levels of betatrophin in pancreatic cancer-associated diabetes.
    Susanto H; Liu TY; Chen CC; Purnomo JD; Chen SF; Wang CH
    Oncotarget; 2016 Jul; 7(27):42330-42339. PubMed ID: 27276680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
    Chung JC; Oh MJ; Choi SH; Bae CD
    ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer.
    Cai CY; Zhai LL; Wu Y; Tang ZG
    Eur J Surg Oncol; 2015 Feb; 41(2):228-35. PubMed ID: 25434328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
    Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
    Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.